CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers
Immunotherapy has been growing in the past decade as a therapeutic alternative for cancer treatment. In this chapter, we deal with CAR-T cells, genetically engineered autologous T cells to express a chimeric receptor specific for an antigen expressed on tumor cell surface. While this type of personalized therapy is revolutionizing cancer treatment, especially B cell malignancies, it has some challenging limitations. Here, we discuss the basic immunological and technological aspects of CAR-T cell therapy, the limitations that have compromised its efficacy and safety, and the current proposed strategies to overcome these limitations, thereby allowing for greater therapeutic application of CAR-T cells.
Key wordsCAR-T cells Chimeric antigen receptor Immunotherapy T cells
This work was financially supported by FAPESP (2012/23228-4, 2016/08374- 5, 2017/09491-8), CTC Center for Cell-based Therapies (FAPESP 2013/08135-2) and National Institute of Science and Technology in Stem Cell and Cell Therapy (CNPq 573754-2008-0 and FAPESP 2008/578773). The authors also acknowledge financial support from Secretaria Executiva do Ministério da Saúde (SE/MS), Departamento de Economia da Saúde, Investimentos e Desenvolvimento (DESID/SE), Programa Nacional de Apoio à Atenção Oncológica (PRONON) Process 25000.189625/2016-16.
- 4.Batlevi CL, Matsuki E, Brentjens RJ et al (2015) Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13:1–17Google Scholar
- 21.U.S. Food & Drug Administration (2017) Kymriah (tisagenlecleucel). https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm573706.htm
- 24.Graham C, Yallop D, Jozwik A (2017) Preliminary results of UCART19, an allogeneic Anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia. Blood 130:887Google Scholar
- 27.Barlow B, Barlow A, Freyer C (2018) CAR-T cells: driving a new era of oncology immunotherapy. US Pharm 43(11):15–22Google Scholar